Study on patients with advanced liver cancer who have received chemotherapy and have undergone liver transplant
Not Applicable
- Conditions
- Health Condition 1: C220- Liver cell carcinoma
- Registration Number
- CTRI/2024/03/064473
- Lead Sponsor
- Department of hepatology Gleneagles Hospital Super speciality and transplant centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
HCC downstaged with systemic therapy with or without locoregional therapy to within UCSF criteria
Exclusion Criteria
1.Extrahepatic metastasis
2.Poor performance status
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Overall survival at 1 year post transplant and end of study- Transplant Benefit (comparison between the 4 groups) <br/ ><br>2. Recurrence free survival at 1 year post transplant and end of study (Group 1, 4) <br/ ><br>3. Recurrence rate at 1 year post transplant and end of study (Group 1, 4) <br/ ><br>Timepoint: 3 years <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1. Rejection rate over 1 year (Group 1, 4) <br/ ><br>2. Surgery related complications – bleeding, wound healing, biliary complications, infections (Group 1, 4) <br/ ><br>3. Duration of stable disease before transplant – correlation with recurrence (Group 1, 4) <br/ ><br>4. Tumour characteristics on explant histology – correlation with recurrence (Group 1, 4) <br/ ><br>5. Pre Transplant Response to Systemic therapy – partial or complete - correlation with recurrence- Radiological & biochemical (Group 1, 4) <br/ ><br>6. Recurrent disease – intrahepatic or extrahepatic (Group 1, 4)Timepoint: 3 years